Outcome MeasurePTSD

PCL-C

PTSD Checklist – Civilian Version

2 Papers in Blossom

Outcome Data Across Studies

Reported results for PCL-C across 1 study with quantitative data.

Papers Using PCL-C

Open Accessindividual

Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial

In a double‑blind, placebo‑controlled within‑participant randomised trial of 16 adults stratified by baseline nonconscious‑threat–evoked amygdala activity, 120 mg MDMA acutely reduced amygdala and subgenual ACC activity, increased sgACC–amygdala connectivity, and raised likability of threat expressions in the high‑reactivity subgroup (NTNA+) versus the low‑reactivity subgroup. These results indicate that baseline neuroimaging of negative affect circuitry can identify biomarkers to personalise MDMA‑based therapies.

Published
Journal
JAMA Network Open
Authors
Zhang, X., Hack, L. M., Bertrand, C., Hilton, R., Gray, N. J., Boyar, L., Laudie, J., Heifets, B. D., Suppes, T., Van Roessel, P. J., Rodriguez, C. I., Deisseroth, K., Knutson, B., Williams, L. M.
Open Accessindividual

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial

This Phase II clinical trial (n=26) finds that MDMA-assisted psychotherapy (75-125 mg) led to significant and sustained decreases in PTSD (CAPS-IV) scores as compared to an active placebo (30 mg). At the 12-month follow-up, the average CAPS-IV score had dropped from 87 to 39 (67% no longer qualified for PTSD diagnosis).

Published
Journal
Lancet Psychiatry
Authors
Mithoefer, A. T., Mithoefer, M. C., Feduccia, A. A., Jerome, L., Wagner, M. T., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Doblin, R.

Quick Facts

Full Name
PTSD Checklist – Civilian Version
Domain
PTSD
Papers Indexed
2
Score Range
17–85
Interpretation
Lower = better
Unit
points
All Measures